I recently watched an episode of one of my favourite TV shows, the Good Doctor. The episode revolved around how a man named Wyatt was rushed into the ER as he had a perforated valve and needed ...

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging AAV.SPR capsid for central retina transduction without foveal detachment risks.

Since the chromosomal regions for potential mutations on chromosomes 6p, 4q and 16q are already known, the identification of a gene responsible for autosomal dominant inherited CVID is more than ...

Aitana, born two months earlier, had been diagnosed with severe combined immunodeficiency of adenosine deaminase (ADA-SCID), a rare ... Her immune system is fully functional, thanks to gene therapy — ...

Tyler Perry reminds us that starting therapy is never too late. The director was recently a guest on The View and revealed that he began therapy for the first time at 54. Perry said a question ...

While I’m not a substitute for professional therapy, I can offer comforting advice, coping strategies, and a safe, judgment-free space to express yourself. How are you feeling today?” ...

But who owns the most ADA? It is wise for buyers to understand the movements of crypto whales — individuals who have the power to influence market prices due to the large size of their trades. ADA saw ...

MyPEAK-1 is designed to test TN-201 as a one-time gene replacement therapy for a type of heart disease called MYBPC3-associated hypertrophic cardiomyopathy. Citing data from three patients in the ...

BHUBANESWAR: In a significant medical breakthrough, India’s first human gene therapy with a lentiviral vector for severe haemophilia-A has been found to be successful with zero bleeding rate in ...

Shorter holding periods have traditionally indicated waning investor confidence, which could lead to selloffs. If this trend continues, ADA's price may struggle to maintain its position above $1.16.